KR20190125653A - Organic germanium assisted yeast fermentated material having skin whitening, skin antiwrinkle and antiinflammation effect - Google Patents
Organic germanium assisted yeast fermentated material having skin whitening, skin antiwrinkle and antiinflammation effect Download PDFInfo
- Publication number
- KR20190125653A KR20190125653A KR1020180049721A KR20180049721A KR20190125653A KR 20190125653 A KR20190125653 A KR 20190125653A KR 1020180049721 A KR1020180049721 A KR 1020180049721A KR 20180049721 A KR20180049721 A KR 20180049721A KR 20190125653 A KR20190125653 A KR 20190125653A
- Authority
- KR
- South Korea
- Prior art keywords
- organic germanium
- yeast
- skin
- yeast fermentation
- wrinkle
- Prior art date
Links
- 240000004808 Saccharomyces cerevisiae Species 0.000 title claims abstract description 99
- 229910052732 germanium Inorganic materials 0.000 title claims abstract description 68
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 title claims abstract description 66
- 230000001153 anti-wrinkle effect Effects 0.000 title claims abstract description 31
- 230000002087 whitening effect Effects 0.000 title claims abstract description 29
- 230000000694 effects Effects 0.000 title description 12
- 239000000463 material Substances 0.000 title description 3
- 238000000855 fermentation Methods 0.000 claims abstract description 92
- 230000004151 fermentation Effects 0.000 claims abstract description 91
- 239000000284 extract Substances 0.000 claims abstract description 44
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 33
- 239000000203 mixture Substances 0.000 claims abstract description 27
- 244000075850 Avena orientalis Species 0.000 claims abstract description 19
- 235000007164 Oryza sativa Nutrition 0.000 claims abstract description 19
- 235000009566 rice Nutrition 0.000 claims abstract description 19
- 235000019156 vitamin B Nutrition 0.000 claims abstract description 12
- 239000011720 vitamin B Substances 0.000 claims abstract description 12
- 229940046001 vitamin b complex Drugs 0.000 claims abstract description 11
- 238000004519 manufacturing process Methods 0.000 claims abstract description 10
- 229940041514 candida albicans extract Drugs 0.000 claims abstract description 9
- 239000012138 yeast extract Substances 0.000 claims abstract description 9
- 241000894006 Bacteria Species 0.000 claims abstract description 6
- 240000007594 Oryza sativa Species 0.000 claims abstract 4
- 239000000047 product Substances 0.000 claims description 22
- 239000002994 raw material Substances 0.000 claims description 12
- 239000002537 cosmetic Substances 0.000 claims description 9
- 239000004480 active ingredient Substances 0.000 claims description 8
- 241000235070 Saccharomyces Species 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 230000036541 health Effects 0.000 claims description 4
- XEABSBMNTNXEJM-UHFFFAOYSA-N propagermanium Chemical compound OC(=O)CC[Ge](=O)O[Ge](=O)CCC(O)=O XEABSBMNTNXEJM-UHFFFAOYSA-N 0.000 claims description 4
- 241001030162 Debaryomyces sp. Species 0.000 claims description 3
- 241000235088 Saccharomyces sp. Species 0.000 claims description 3
- 235000013376 functional food Nutrition 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- 230000000153 supplemental effect Effects 0.000 claims description 3
- 239000013589 supplement Substances 0.000 claims description 2
- 125000000082 organogermanium group Chemical group 0.000 claims 1
- 229950002828 propagermanium Drugs 0.000 claims 1
- 239000007864 aqueous solution Substances 0.000 abstract description 21
- 210000003491 skin Anatomy 0.000 description 45
- 210000004027 cell Anatomy 0.000 description 21
- 239000000706 filtrate Substances 0.000 description 20
- 235000007319 Avena orientalis Nutrition 0.000 description 15
- 241000209094 Oryza Species 0.000 description 15
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 12
- 230000032683 aging Effects 0.000 description 12
- 230000005764 inhibitory process Effects 0.000 description 11
- 238000002835 absorbance Methods 0.000 description 9
- 230000009759 skin aging Effects 0.000 description 9
- 239000000243 solution Substances 0.000 description 9
- 102000003425 Tyrosinase Human genes 0.000 description 8
- 108060008724 Tyrosinase Proteins 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 239000001301 oxygen Substances 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 8
- 108010050808 Procollagen Proteins 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 102000008186 Collagen Human genes 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 5
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 210000002540 macrophage Anatomy 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 description 4
- 101710200814 Melanotropin alpha Proteins 0.000 description 4
- 241000218206 Ranunculus Species 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000003020 moisturizing effect Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 description 4
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 244000300264 Spinacia oleracea Species 0.000 description 3
- 235000009337 Spinacia oleracea Nutrition 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 230000003712 anti-aging effect Effects 0.000 description 3
- 235000013361 beverage Nutrition 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 230000008099 melanin synthesis Effects 0.000 description 3
- 230000037333 procollagen synthesis Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000004065 semiconductor Substances 0.000 description 3
- 229960004441 tyrosine Drugs 0.000 description 3
- VOUAQYXWVJDEQY-QENPJCQMSA-N 33017-11-7 Chemical compound OC(=O)CC[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N1[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)CCC1 VOUAQYXWVJDEQY-QENPJCQMSA-N 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 2
- 108010075254 C-Peptide Proteins 0.000 description 2
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 2
- 238000011891 EIA kit Methods 0.000 description 2
- 102000016942 Elastin Human genes 0.000 description 2
- 108010014258 Elastin Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 229930003471 Vitamin B2 Natural products 0.000 description 2
- 238000001467 acupuncture Methods 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000002500 effect on skin Effects 0.000 description 2
- 229920002549 elastin Polymers 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 235000012907 honey Nutrition 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000008057 potassium phosphate buffer Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 229950004871 repagermanium Drugs 0.000 description 2
- 229960002477 riboflavin Drugs 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 235000019164 vitamin B2 Nutrition 0.000 description 2
- 239000011716 vitamin B2 Substances 0.000 description 2
- 230000037303 wrinkles Effects 0.000 description 2
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 208000001408 Carbon monoxide poisoning Diseases 0.000 description 1
- 241001340526 Chrysoclista linneella Species 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 230000009946 DNA mutation Effects 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 102000016387 Pancreatic elastase Human genes 0.000 description 1
- 108010067372 Pancreatic elastase Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 229930003270 Vitamin B Natural products 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003537 Vitamin B3 Natural products 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000003679 aging effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000000513 bioprotective effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- -1 lipid peroxide Chemical class 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 229910052755 nonmetal Inorganic materials 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 125000000962 organic group Chemical group 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- 230000008845 photoaging Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- JZRWCGZRTZMZEH-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000009772 tissue formation Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019160 vitamin B3 Nutrition 0.000 description 1
- 239000011708 vitamin B3 Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
- 230000037330 wrinkle prevention Effects 0.000 description 1
- 239000007218 ym medium Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
- A23L33/165—Complexes or chelates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/101—Addition of antibiotics, vitamins, amino-acids, or minerals
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/104—Fermentation of farinaceous cereal or cereal material; Addition of enzymes or microorganisms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Birds (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Botany (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 피부 미백, 피부 항주름 및 항염증 효능을 갖는 유기게르마늄 보조 효모 발효물 및 그의 제조방법에 관한 것으로 특히, 미강 추출물과 귀리 추출물의 효모 발효 시, 유기게르마늄을 첨가하여 효모 발효시킴으로써 개선된 피부 미백, 피부 항주름 및 항염증 효능을 갖는 피부 미백, 피부 항주름 및 항염증 효능을 갖는 유기게르마늄 보조 효모 발효물 및 그의 제조방법에 관한 것이다. The present invention relates to an organic germanium supplementary yeast fermentation having a skin whitening, anti-wrinkle and anti-inflammatory effect and a method for preparing the same, and in particular, in yeast fermentation of rice bran extract and oat extract, it is improved by fermenting yeast by adding organic germanium. The present invention relates to an organic germanium supplementary yeast fermentation product having skin whitening, skin anti-wrinkle and anti-inflammatory effects, and a method for preparing the same.
최근 생활수준이 향상됨에 따라 현대인들은 건강한 신체를 유지하는 것에 더하여 건강한 피부를 유지하는 데에도 많은 관심을 기울이고 있다. 따라서 피부미용 증진과 피부노화 방지에 대한 관심이 높아지고 있다.With the recent increase in living standards, modern people are paying more attention to maintaining healthy skin in addition to maintaining a healthy body. Therefore, interest in enhancing skin beauty and preventing skin aging is increasing.
인체의 가장 큰 기관으로서 전체 인체 부피의 약 16%를 차지하고 있는 피부는 외부환경과 직접 접해 있으면서, 인체 안으로 침입하려는 치명적인 많은 유해인자, 예를 들면, 온도, 습도 및 자외선 등으로부터 인체를 보호하는 중요한 보호막 역할을 담당한다. 그러나, 나이가 들어감에 따라 각종 오염물질, 강한 자외선, 스트레스 및 영양결핍 등으로 인해 피부 세포들이 손상을 입게 되고, 세포 증식이 제대로 이루어지지 않게 되어 피부에 주름, 탄력 손실 및 각질화 등이 발생한다.As the largest organ of the human body, which occupies about 16% of the total body volume, the skin is in direct contact with the external environment and is important to protect the body from many deadly harmful factors such as temperature, humidity, and ultraviolet radiation. Act as a shield. However, as they age, skin cells are damaged due to various contaminants, strong ultraviolet rays, stress, and malnutrition, and cell proliferation is not performed properly, resulting in wrinkles, loss of elasticity, and keratinization.
피부 노화는 크게 자연 노화 (혹은 내인성 노화)와 외적 노화로 구분되며 (Doris EB, Cosmet. Toiletries, 1996, 111, 31), 자연 노화 (내인성 노화)는 유전적인 요소에 영향을 받기 때문에 인위적인 조절이 어려운 반면 외적노화는 환경적인 요소에 영향을 받기 때문에 인위적인 조절이 비교적 용이하다. 대표적인 외적 노화 인자로는 자외선, 활성 산소종(reactive oxygen species) 및 스트레스 등으로, 가장 두드러진 외적인 노화 현상은 주름 형성이며(Daniell HW, Ann. Intern. Med., 1971, 75(6), 873; Grove GL 등, J. Am. Acad. Dermatol., 1989, 21(3), 631; Griffiths CE 등, Arch. Dermatol., 1992, 128, 347) 그 결과 피부 탄력이 현저히 감소하게 된다.Skin aging is largely divided into natural aging (or endogenous aging) and external aging (Doris EB, Cosmet. Toiletries, 1996, 111, 31), and natural aging (endogenous aging) is influenced by genetic factors, so artificial regulation On the other hand, external aging is relatively easy to artificially adjust because of environmental factors. Representative external aging factors include ultraviolet light, reactive oxygen species and stress, and the most prominent external aging phenomenon is wrinkle formation (Daniell HW, Ann. Intern. Med., 1971, 75 (6), 873; Grove GL et al., J. Am. Acad. Dermatol., 1989, 21 (3), 631; Griffiths CE et al., Arch. Dermatol., 1992, 128, 347). As a result, skin elasticity is significantly reduced.
피부의 노화 기작을 규명하기 위한 여러 연구들이 진행되어 여러 가지 피부 노화의 원인들이 밝혀졌다. 피부가 온도의 변화, 습도의 저하 또는 바람 등에 의해 건조하게 되면 외부에 대한 방어벽으로서의 피부 생리 활성이 저하되어 노화가 촉진된다. 또한, 유해 활성 산소종 또는 자유 라디칼에 피부가 노출되면 체내의 산화 작용에 의해 과산화 지질이 생성되고 피부를 구성하는 여러 단백질들의 변형을 유발하게 된다. 자외선에 의해 야기되는 광노화 메커니즘 중의 하나는 자유 라디칼 경로를 경유하는 것이다 (Harman D,J. Gerontol., 1956, 11(3), 298). 자유 라디칼들은 피부 콜라겐 등의 결합 조직 형성 파괴, 세포막 기능저해, DNA 변이 촉진, 단백질 작용 변형, 세포간 에너지 전이, 신진 대사와 관련된 분자들의 변형 등을 유발하는 것으로 알려져 있다 (Lavker RM 및 Kligman AM, J. Invest. Dermatol., 1988, 90, 325). 노화에 자유 라디칼이 관여한다는 사실은 자유 라디칼을 불활성화시키는 항산화제 또는 여러가지 화학적 소거제들을 사용하여 노화 과정을 지연시킬 수 있다는 것을 의미한다.Various studies have been conducted to investigate the mechanism of aging of the skin, revealing various causes of skin aging. When the skin is dried by a change in temperature, a decrease in humidity or wind, the skin physiological activity as a protective barrier against the outside is lowered to promote aging. In addition, exposure of the skin to harmful reactive oxygen species or free radicals causes oxidative action in the body to produce lipid peroxide and cause modification of the various proteins that make up the skin. One of the photoaging mechanisms caused by ultraviolet light is via free radical pathways (Harman D, J. Gerontol., 1956, 11 (3), 298). Free radicals are known to cause breakdown of connective tissue formation, such as cutaneous collagen, cell membrane dysfunction, facilitating DNA mutations, altering protein function, intercellular energy transfer, and metabolism related molecules (Lavker RM and Kligman AM, J. Invest.Drmatol., 1988, 90, 325). The fact that free radicals are involved in aging means that antioxidants or various chemical scavengers that inactivate the free radicals can be used to delay the aging process.
또한, 피부의 진피조직 속에는 콜라겐(collagen)과 피부의 탄력성에 관련된 엘라스틴(elastine)이 그물망 구조를 형성하고 있는데, 이러한 그물망 구조가 깨어지면서 즉, 엘라스틴이 엘라스틴 분해효소(elastase)에 의해 분해되어 피부가 처지고 주름이 생기므로 내인성 피부노화가 발생한다. 그러므로, 피부노화의 주원인 중의 하나인 엘라스틴 분해효소(elastase)의 활성을 저하시킴으로써 피부노화를 억제할 수 있다.In addition, collagen and elastine related to the elasticity of the skin form a network structure in the dermal tissue of the skin. As the network structure is broken, that is, elastin is decomposed by elastin degrading enzyme (elastase). And wrinkling causes endogenous skin aging. Therefore, skin aging can be suppressed by lowering the activity of elastinase, one of the main causes of skin aging.
종래에는 피부노화 방지를 위하여 거의 피부 표면에 바르는 화장품에 의존해왔다. 대한민국 공개특허공보 제2001-65755호에는 피부세포 증식, 콜라겐섬유 합성 촉진 등 피부 주름개선 및 탄력증진 효과가 있는 베타-1,3-글루칸과 인삼사포닌 함유 외용제 조성물이 개시되어 있으며, 대한민국 특허등록 제423,521호에는 주름개선 효과, 콜라겐 합성촉진효과, 광접촉에 의한 손상피부 회복 효과, 보습 효과를 나타내는 인삼다당체를 함유한 화장품 조성물이 개시되어 있다. 그러나 직접 피부 표면에 적용되는 외용제 및 화장품은 진피층까지 흡수되지 못하고, 표피에만 작용하므로 피부노화 방지효과가 일시적이고, 그 부작용으로 피부가 손상되기도 하는 문제점이 있다. 또한 체내에 있는 활성산소를 제거하지 못하여, 활성산소에 의한 노화작용을 막기에는 한계가 있었다.Conventionally, it has been relied on cosmetics that are almost applied to the skin surface to prevent skin aging. Korean Unexamined Patent Publication No. 2001-65755 discloses a beta-1,3-glucan and ginseng saponin-containing external preparation composition having skin wrinkle improvement and elasticity enhancing effects such as skin cell proliferation and collagen fiber synthesis. No. 423,521 discloses a cosmetic composition containing ginseng polysaccharides that exhibits an anti-wrinkle effect, a collagen synthesizing effect, a damaged skin recovery effect by optical contact, and a moisturizing effect. However, the external preparations and cosmetics applied directly to the skin surface are not absorbed up to the dermal layer, and act only on the epidermis, so that the skin aging prevention effect is temporary, and there is a problem that the skin is damaged as a side effect. In addition, the active oxygen in the body can not be removed, there was a limit to prevent the aging action by the active oxygen.
또한, 화학물질로 이루어진 미용 식품 조성물들은 그 부작용이 있어 많은 폐단을 초래하는 이유로, 천연물질 등을 이용하여 장기간 사용 시에도 안정성이 높은 피부노화 방지 및 개선 물질을 개발하의 필요성이 절실히 요구되고 있는 실정이다.In addition, the cosmetic food compositions made of chemicals have a lot of side effects that cause a lot of discontinuation, the situation is urgently required to develop a highly stable skin aging prevention and improvement material even when using for a long time using natural materials. to be.
대한민국 등록특허 등록번호 제10-1187227호(발명의 명칭: 유산균과 효모의 복발효법을 이용한 미나리음료 및 그 제조방법)는 "본 발명은 젖산균과 효모를 이용한 복발효를 통해 건강에 도움이 되는 폴리페놀 성분을 포함하는 미나리를 이용하는 전혀 새로운 종류의 유산균과 효모의 복발효법을 이용한 미나리음료 및 그 제조방법에 관한 것으로서, 미나리를 분쇄하고, 젖산균과 효모를 준비한 다음, 분쇄된 미나리에 젖산균을 접종하여 일차 발효를 수행하고, 일차 발효가 끝난 배양액에 효모를 접종하여 이차 발효를 수행하여 복발효된 미나리 음료를 얻게 된다."고 기술하고 있다.Republic of Korea Patent Registration No. 10-1187227 (name of the invention: the buttercup beverage using lactic acid bacteria and yeast double fermentation method and its manufacturing method) is "the present invention is a poly to help health through the double fermentation using lactic acid bacteria and yeast The present invention relates to a buttercup beverage using a novel fermentation method of lactic acid bacteria and yeast using a buttercup containing a phenolic component, and to a method of manufacturing the same. The primary fermentation is carried out, and the fermentation of the finished fermentation broth is inoculated with yeast to obtain the fermented buttercup beverage. ”
대한민국 등록특허 등록번호 제10-1177915호(발명의 명칭: 시금치 추출물의 효모발효액을 함유하는 주름 예방 및 노화방지용 피부외용제 조성물)는 "본 발명은 시금치 추출물에 효모를 접종하고 배양시켜 얻은 시금치 추출물의 효모발효액을 활성성분으로 함유하는 주름 예방 및 노화 방지용 피부외용제 조성물에 관한 것이다. 상기 시금치 추출물의 효모발효액은 프로콜라겐(procollagen)의 합성을 촉진하고 콜라게네이즈(collagenase)의 생성을 억제하는 효과가 있다."고 기술하고 있다.Republic of Korea Patent Registration No. 10-1177915 (name of the invention: skin anti-aging composition for wrinkle prevention and anti-aging containing yeast fermentation of spinach extract) "The present invention is a spinach extract obtained by inoculating and incubating The present invention relates to an anti-wrinkle and anti-aging skin external composition comprising a yeast fermentation solution as an active ingredient The yeast fermentation solution of the spinach extract has an effect of promoting the synthesis of procollagen and inhibiting the production of collagenase. It is. "
대한민국 등록특허 등록번호 제10-1824179호(발명의 명칭: 더위지기 효모 발효물을 포함하는 보습 및 항염증 화장료 조성물)는 "본 발명은 우수한 보습 및 항염증 효능을 갖는 더위지기 효모 발효물을 포함하는 화장료 조성물 및 그 제조방법에 관한 것으로, 보다 구체적으로는 더위지기를 효모발효시킨 발효물을 화장료 조성물 내 유효성분으로 포함함으로써, 발효 전보다 피부자극이 감소하며, 증가된 보습 효과, 항산화 효과 및 항염증 효과를 갖는 것이다."고 기술하고 있다.Republic of Korea Patent Registration No. 10-1824179 (name of the invention: moisturizing and anti-inflammatory cosmetic composition comprising heat keeper yeast fermentation) "The present invention includes a heat keeper yeast fermentation having excellent moisturizing and anti-inflammatory efficacy The present invention relates to a cosmetic composition and a method of manufacturing the same, and more specifically, by including a fermented product obtained by fermenting a heat scavenger as an active ingredient in the cosmetic composition, skin irritation is reduced, and an increased moisturizing effect, an antioxidant effect, and an anti-fermentation effect than before fermentation. It has an inflammatory effect. "
본 발명은 미강 추출물과 귀리 추출물의 효모 발효 시, 유기게르마늄을 첨가하여 효모 발효시킴으로써 개선된 피부 미백, 피부 항주름 및 항염증 효능을 갖는 피부 미백, 피부 항주름 및 항염증 효능을 갖는 유기게르마늄 보조 효모 발효물 및 그의 제조방법을 제공함을 목적으로 한다.The present invention is an organic germanium supplement having improved skin whitening, skin anti-wrinkle and anti-inflammatory effects by yeast fermentation by adding organic germanium at the time of yeast fermentation of rice bran extract and oat extract. It is an object to provide a yeast fermented product and a method for producing the same.
본 발명에 따른 피부 미백, 피부 항주름 및 항염증 효능을 갖는 유기게르마늄 보조 효모 발효물은 미강 추출물, 귀리 추출물, 당분, 비타민 B 복합 수용액 및 효모 추출물을 포함하는 원물 혼합물에 유기게르마늄을 첨가하고, 효모균을 접종하고, 배양시켜 수득된 것이다.The organic germanium auxiliary yeast fermentation product having skin whitening, skin anti-wrinkle and anti-inflammatory effects according to the present invention is added to the organic mixture of the source mixture comprising rice bran extract, oat extract, sugar, vitamin B complex aqueous solution and yeast extract, Obtained by inoculating and culturing yeast.
상기 효모균은 사카로마이세스 속(Saccharomyces sp .), 데브리오마이세스 속(Debaryomyces sp .) 및 아우레오바시둠 속(Aureobasidum sp .)으로 이루어지는 군으로부터 선택되는 효모일 수 있다.The yeast is Saccharomyces sp . ), Debaryomyces sp . And Aureobasidum sp . Yeast selected from the group consisting of
상기 효모균은 사카로마이세스 폼베(Saccharomyces pombe) 균일 수 있다.The yeast is Saccharomyces Saccharomyces pombe ) can be uniform.
상기 유기게르마늄은 레파게르마늄, 프로파게르마늄 또는 이들의 혼합물일 수 있다.The organic germanium may be lepagermanium, propagernium or a mixture thereof.
상기 원물 추출물에의 유기게르마늄의 첨가량은 원물 추출물 총 중량을 기준으로 0.1 내지 10중량%의 범위 이내일 수 있다.The amount of the organic germanium added to the raw extract may be in the range of 0.1 to 10% by weight based on the total weight of the raw extract.
본 발명에 따른 피부 미백, 피부 항주름 및 항염증 효능을 갖는 유기게르마늄 보조 효모 발효물 함유 화장품은 상기 피부 미백, 피부 항주름 및 항염증 효능을 갖는 유기게르마늄 보조 효모 발효물을 유효성분으로 포함한다.The organic-germanium auxiliary yeast fermentation product having skin whitening, skin anti-wrinkle and anti-inflammatory effects according to the present invention comprises the organic germanium auxiliary yeast fermentation having the skin whitening, skin anti-wrinkle and anti-inflammatory effects as an active ingredient. .
본 발명에 따른 피부 미백, 피부 항주름 및 항염증 효능을 갖는 유기게르마늄 보조 효모 발효물 함유 건강기능식품은 상기 피부 미백, 피부 항주름 및 항염증 효능을 갖는 유기게르마늄 보조 효모 발효물을 유효성분으로 포함한다.The health functional food containing organic germanium supplementary yeast fermentation having skin whitening, skin anti-wrinkle and anti-inflammatory effects according to the present invention is an organic germanium supplementary yeast fermentation having the skin whitening, skin anti-wrinkle and anti-inflammatory effect as an active ingredient Include.
본 발명에 따른 피부 미백, 피부 항주름 및 항염증 효능을 갖는 유기게르마늄 보조 효모 발효물의 제조방법은 (1) 미강 추출물, 귀리 추출물, 당분, 비타민 B 복합 수용액 및 효모 추출물을 포함하는 원물 혼합물을 준비하는 혼합단계; (2) 상기 원물 혼합물에 유기게르마늄을 첨가하는 유기게르마늄 첨가단계; 및 (3) 유기게르마늄이 첨가된 원물 혼합물에 효모균을 접종하고, 배양시키는 배양단계;를 포함한다.According to the present invention, a method for preparing an organic germanium supplementary yeast fermentation product having skin whitening, anti-wrinkle and anti-inflammatory effects is prepared by (1) preparing a raw mixture including rice bran extract, oat extract, sugar, aqueous solution of vitamin B complex and yeast extract Mixing step; (2) an organic germanium addition step of adding organic germanium to the raw material mixture; And (3) incubating the inoculated yeast with the organic germanium-added raw material mixture and culturing.
본 발명에 따르면, 미강 추출물과 귀리 추출물의 효모 발효 시, 유기게르마늄을 첨가하여 효모 발효시킴으로써 개선된 피부 미백, 피부 항주름 및 항염증 효능을 갖는 피부 미백, 피부 항주름 및 항염증 효능을 갖는 유기게르마늄 보조 효모 발효물 및 그의 제조방법을 제공하는 효과가 있으며, 이는 화장품 등의 원료로 사용될 수 있다.According to the present invention, in yeast fermentation of rice bran extract and oat extract, organic whitening having skin whitening, skin anti-wrinkle and anti-inflammatory effects by adding organic germanium to yeast fermentation, and having organic anti-wrinkle and anti-inflammatory effects There is an effect of providing a germanium auxiliary yeast fermentation and a method for producing the same, which can be used as a raw material such as cosmetics.
도 1은 본 발명의 실시예 1에서 수득되는 유기게르마늄 보조 효모 발효물의 여과물(이하 "유기게르마늄-효모 발효물"이라 함)의 세포독성을 실험하기 위하여, Fibroblast CCD986-sk 세포주(A)와 Macrophage Raw264.7 세포주(B)에 유기게르마늄-효모 발효물을 농도별로 처리하여 MTT assay를 시행한 결과를 나타낸 도면이다.
도 2는 본 발명의 유기게르마늄-효모 발효물(A)과 효모발효 여과물(B: 유기게르마늄을 수반함이 없이 효모 발효된 발효물의 여과물), 유기게르마늄으로서 레파게르마늄 수용액(C)의 프로콜라겐 합성능을 비교 실험하기 위하여, Fibroblast CCD986-sk 세포주에 유기게르마늄-효모 발효물을 농도별로 처리하여 프로콜라겐을 측량한 결과를 나타낸 도면이다.
도 3은 본 발명의 유기게르마늄-효모 발효물(A)과 효모발효 여과물(B), 유기게르마늄으로서 레파게르마늄 수용액(C)의 멜라닌 생성 억제능을 비교 실험하기 위하여, melanoma B16F10 세포주에 유기게르마늄-효모 발효물을 농도별로 처리하여 생성된 멜라닌을 정량한 결과를 나타낸 도면이다.
도 4는 본 발명의 유기게르마늄-효모 발효물(A)과 효모발효 여과물(B), 유기게르마늄으로서 레파게르마늄 수용액(C)의 항염증능을 비교 실험하기 위하여, Macrophage Raw264.7 세포주에 유기게르마늄-효모 발효물을 농도별로 처리하여 TNF-α의 분비량을 측정한 결과를 나타낸 도면이다.
도 5는 본 발명의 유기게르마늄-효모 발효물(A)과 효모발효 여과물(B), 유기게르마늄으로서 레파게르마늄 수용액(C)의 티로시나아제 억제율을 비교 실험하기 위하여, in vitro 티로시나아제 활성 저해시험을 수행한 결과를 나타낸 도면이다.1 is a fibroblast CCD986-sk cell line (A) for experimenting with the cytotoxicity of the filtrate of the organic germanium auxiliary yeast fermentation obtained in Example 1 of the present invention (hereinafter referred to as "organic germanium- yeast fermentation") Macrophage Raw264.7 cell line (B) is a diagram showing the results of MTT assay by treating the organic germanium- yeast fermentation by concentration.
Figure 2 is an organic germanium- yeast fermentation product (A) of the present invention and the yeast fermentation filtrate (B: the filtrate of yeast fermentation without the accompanying organic germanium), progear of aqueous solution of lepagermanium (C) as organic germanium In order to compare the collagen synthesis ability, it is a figure showing the results of procollagen measurement by treating the organic germanium- yeast fermentation by concentration in the Fibroblast CCD986-sk cell line.
Figure 3 is an organic germanium- yeast fermentation product (A) of the present invention, yeast fermentation filtrate (B), organic germanium to melanoma B16F10 cell line to inhibit the melanin production inhibition of aqueous solution (C) as organic germanium Figure showing the results of quantifying the melanin produced by treating the yeast fermentation by concentration.
Figure 4 is an organic germanium- yeast fermentation product (A) of the present invention and the yeast fermentation filtrate (B), in order to compare the anti-inflammatory effect of the aqueous solution of lepagermanium (C) as organic germanium, organic to Macrophage Raw264.7 cell line It is a figure which shows the result of measuring the secretion amount of TNF- (alpha) by processing germanium yeast fermentation by concentration.
Figure 5 is in vitro tyrosinase activity to compare the tyrosinase inhibition rate of the organic germanium- yeast fermentation product (A) of the present invention and the yeast fermentation filtrate (B), the aqueous solution of lepagermanium (C) as organic germanium, A diagram showing the results of the inhibition test.
이하, 본 발명을 구체적인 실시예를 참조하여 상세히 설명한다.Hereinafter, the present invention will be described in detail with reference to specific examples.
본 발명에 따른 피부 미백, 피부 항주름 및 항염증 효능을 갖는 유기게르마늄 보조 효모 발효물은 미강 추출물, 귀리 추출물, 당분, 비타민 B 복합 수용액 및 효모 추출물을 포함하는 원물 혼합물에 유기게르마늄을 첨가하고, 효모균을 접종하고, 배양시켜 수득된 것임을 특징으로 한다.The organic germanium supplemental yeast fermentation product having skin whitening, skin anti-wrinkle and anti-inflammatory effects according to the present invention is added to the germanium extract to the raw material mixture including rice bran extract, oat extract, sugar, vitamin B complex aqueous solution and yeast extract, It is characterized in that obtained by inoculating and culturing yeast.
상기 효모균은 사카로마이세스 속(Saccharomyces sp .), 데브리오마이세스 속(Debaryomyces sp .) 및 아우레오바시둠 속(Aureobasidum sp .)으로 이루어지는 군으로부터 선택되는 효모일 수 있으며, 바람직하게는 상기 효모균은 사카로마이세스 폼베(Saccharomyces pombe) 균일 수 있다.The yeast is Saccharomyces sp . ), Debaryomyces sp . And Aureobasidum sp . It may be a yeast selected from the group consisting of, preferably the yeast may be Saccharomyces pombe ( Saccharomyces pombe ) uniform.
상기 유기게르마늄은 레파게르마늄, 프로파게르마늄 또는 이들의 혼합물일 수 있다. 유기게르마늄에 대하여 알려진 일반적인 효능은 다음과 같다. The organic germanium may be lepagermanium, propagernium or a mixture thereof. The general efficacy known for organogerium is as follows.
1. 산소 공급작용1. Oxygen supply
인체 세포들이 신진대사를 계속 반복적으로 행하려면 영양소와 산소가 절대 필요하며, 산소부족 시 만성 일산화탄소 중독증, 빈혈, 혈관장애, 심장장애, 저혈압, 세포노화, 정신장애 등의 질환이 발생한다. 최근에 와서 의학자들의 실험에 의해 게르마늄은 산소의 효율적인 활용을 돕는 산소촉매제의 역할을 한다는 사실이 밝혀졌다. 즉, 인체에 유기게르마늄을 공급하게 되면 여분의 산소는 혈액에 생명력을 공급하기 때문에 만성산소결핍 현상에서 벗어나게 된다고 알려지고 있다.Numerous nutrients and oxygen are necessary for the human cells to continue metabolism repeatedly, and when oxygen lacks, diseases such as chronic carbon monoxide poisoning, anemia, vascular disorders, heart disorders, hypotension, cell aging, and mental disorders occur. In recent years, medical experiments have shown that germanium acts as an oxygen catalyst to help the efficient use of oxygen. In other words, when the organic germanium is supplied to the human body, it is known that extra oxygen supplies vitality to the blood, thereby releasing chronic oxygen deficiency.
2. 반도체작용(체내세포의 전류 흐름조절작용): 음이온 효과2. Semiconductor effect (regulation of current flow in body cells): Anion effect
게르마늄의 최대 특징은 전기적인 성질로 금속과 비금속의 중간적 성질을 갖고 있는 반도체인 것이며, 게르마늄의 이런 성질이 바로 인체의 온갖 질병을 치료해 주는 원리가 된다고 하여 기적의 원소라고 불린다. 만일 체내에 이물질이 생기게 되면 4개의 전자 중 바깥쪽 전자가(-)상태가 되어 밖으로 튀어나오고 나머지는 3개는 (+)의 하전상태가 되어 신체와 조화를 이루게 된다. 게르마늄의 이런 역할이 바로 신체의 질병을 치료해주는 원리가 되며, 한방에서 경락과 경혈에 행하는 침이나 뜸, 지압도 마찬가지로 세포의 반도체 흐름을 원활히 하여 질병을 치료하는 똑같은 원리인 것이다.The greatest feature of germanium is the semiconductor, which is an electrical property, which has the intermediate property between metal and nonmetal, and is called a miracle element because this property of germanium is the principle that heals all kinds of diseases of the human body. If a foreign body is created in the body, the outer electrons of the four electrons become (-) state and stick out, and the other three are positively charged state in harmony with the body. This role of germanium is the principle that heals diseases of the body, and the acupuncture, moxibustion, and acupressure of the meridians and acupuncture points in the same medicine is the same principle that treats diseases by smoothing the flow of semiconductor cells.
3. 면역력 강화 작용3. strengthening immunity
인체는 크게 2가지의 면역체계를 가지고 있는데, 첫째는 백혈구에 의한 것으로 체내에 들어온 병원균을 식균작용에 의해 잡아먹는 체계이고, 둘째는 항체에 의한 작용인데 T-임파구에 의해 B-임파구가 형성되어 병원균과 결합하여 그 균을 죽이는 작용을 하는 체계이다. 따라서 암에 걸렸다고 하는 것은 T-임파구 수가 저하되었다는 것을 의미하여 게르마늄은 T-임파구를 증식시켜 암세포, 독성물질, 바이러스 등으로부터 신체를 보호한다. 또한 일본 동경대학교 항산 균병 연구소의 사토박사는 유기게르마늄(Ge-132)의 임상실험에서도 유기게르마늄은 B.R.M(생체방어기구 활성화 물질)의 하나로써 면역조절에 탁월한 효과가 있다고 밝혔다.The human body has two kinds of immune system. First, it is caused by white blood cells, and it is a system that eats pathogens that enter the body by phagocytosis. Second, it is caused by antibodies. B-lymphocytes are formed by T-lymphocytes. It is a system that works by combining pathogens and killing them. Therefore, having cancer means that the number of T-lymphocytes has decreased, and germanium proliferates T-lymphocytes to protect the body from cancer cells, toxic substances, and viruses. Dr. Sato of the Tokyo Institute of Antibacterial and Bacterial Diseases at the University of Tokyo, Japan, also said that organic germanium is one of B.R.M (bioprotective device activating substances) in the clinical trials of organic germanium (Ge-132).
즉, 유기게르마늄은 생체에 대하여 긍정적인 영향을 주는 것으로 알려져 있으며, 본 발명에서는 이러한 유기게르마늄을 이용하여 효모 발효를 촉진하고 유효 생리활성물질의 생성을 촉진하는 것으로 여겨진다.In other words, it is known that organic germanium has a positive effect on the living body, and in the present invention, it is believed that the use of such organic germanium promotes fermentation of yeast and the production of effective bioactive substances.
상기 원물 혼합물은 비타민B1 0.1 내지 10중량%, 비타민 B2 0.01 내지 1중량% 및 비타민B2, 비타민B3 0.1 내지 10중량% 및 잔량으로서 물을 포함하여 이루어지는 비타민 B 복합 수용액을 더 포함할 수 있다.The raw material mixture may further include a vitamin B complex aqueous solution containing 0.1 to 10% by weight of vitamin B1, 0.01 to 1% by weight of vitamin B2, and 0.1 to 10% by weight of vitamin B2 and vitamin B3 and the balance.
상기 미강 추출물 및 귀리 추출물은 미강과 귀리를 열수추출한 것일 수 있다. 미강 추출물과 귀리 추출물을 제조하기 위하여는, 미강과 귀리를 각각 세척, 건조하여 해당 시료 무게의 2 내지 10배의 증류수로 25 내지 100℃에서 2 내지 6시간 동안 열수 추출하는 것으로 수행될 수 있다.The rice bran extract and oat extract may be hot water extracted rice bran and oats. To prepare the rice bran extract and the oat extract, washing and drying the rice bran and oats, respectively, may be performed by hot water extraction for 2 to 6 hours at 25 to 100 ℃ with distilled water of 2 to 10 times the weight of the sample.
상기 당분은 꿀일 수 있다.The sugar may be honey.
상기 원물 혼합물은 미강 추출물 1 내지 10중량%, 귀리 추출물 5 내지 30중량%, 당분 1 내지 3중량%, 비타민 B 복합 수용액 1 내지 1중량%, 효모 추출물 0.05 내지 0.2중량% 및 잔량으로서 물을 포함하여 이루어질 수 있다.The raw material mixture contains 1 to 10% by weight of rice bran extract, 5 to 30% by weight of oat extract, 1 to 3% by weight of sugar, 1 to 1% by weight of a vitamin B complex aqueous solution, 0.05 to 0.2% by weight of yeast extract and the balance as water. It can be done by.
상기 원물 추출물에의 유기게르마늄의 첨가량은 원물 추출물 총 중량을 기준으로 0.1 내지 10중량%의 범위 이내일 수 있다.The amount of the organic germanium added to the raw extract may be in the range of 0.1 to 10% by weight based on the total weight of the raw extract.
상기 원물 추출물에의 사카로마이세스 폼베(Saccharomyces pombe) 균의 접종량은 사카로마이세스 폼베 균을 YM배지에 접종하여 600㎚에서 1.0의 흡광도 값을 나타낼 때까지 확대배양한 배양액 5 내지 20중량%의 범위 이내일 수 있다. Saccharomyces on the Raw Material Extracts pombe ) was inoculated with Saccharomyces pombe on YM medium and expanded until absorbance values of 600 nm and 1.0 were obtained. The culture may be in the range of 5 to 20% by weight.
본 발명에 따른 피부 미백, 피부 항주름 및 항염증 효능을 갖는 유기게르마늄 보조 효모 발효물 함유 화장품은 상기 피부 미백, 피부 항주름 및 항염증 효능을 갖는 유기게르마늄 보조 효모 발효물을 유효성분으로 포함한다.The organic-germanium auxiliary yeast fermentation product having skin whitening, skin anti-wrinkle and anti-inflammatory effects according to the present invention comprises the organic germanium auxiliary yeast fermentation having the skin whitening, skin anti-wrinkle and anti-inflammatory effects as an active ingredient. .
본 발명에 따른 피부 미백, 피부 항주름 및 항염증 효능을 갖는 유기게르마늄 보조 효모 발효물 함유 건강기능식품은 상기 피부 미백, 피부 항주름 및 항염증 효능을 갖는 유기게르마늄 보조 효모 발효물을 유효성분으로 포함한다.The health functional food containing organic germanium supplementary yeast fermentation having skin whitening, skin anti-wrinkle and anti-inflammatory effects according to the present invention is an organic germanium supplementary yeast fermentation having the skin whitening, skin anti-wrinkle and anti-inflammatory effect as an active ingredient Include.
본 발명에 따른 피부 미백, 피부 항주름 및 항염증 효능을 갖는 유기게르마늄 보조 효모 발효물의 제조방법은 (1) 미강 추출물, 귀리 추출물, 당분, 비타민 B 복합 수용액 및 효모 추출물을 포함하는 원물 혼합물을 준비하는 혼합단계; (2) 상기 원물 혼합물에 유기게르마늄을 첨가하는 유기게르마늄 첨가단계; 및 (3) 유기게르마늄이 첨가된 원물 혼합물에 효모균을 접종하고, 배양시키는 배양단계;를 포함한다.According to the present invention, a method for preparing an organic germanium supplementary yeast fermentation product having skin whitening, anti-wrinkle and anti-inflammatory effects is prepared by (1) preparing a raw mixture including rice bran extract, oat extract, sugar, aqueous solution of vitamin B complex and yeast extract Mixing step; (2) an organic germanium addition step of adding organic germanium to the raw material mixture; And (3) incubating the inoculated yeast with the organic germanium-added raw material mixture and culturing.
이하에서 본 발명의 바람직한 실시예 및 비교예들이 기술되어질 것이다.Hereinafter, preferred embodiments and comparative examples of the present invention will be described.
이하의 실시예들은 본 발명을 예증하기 위한 것으로서 본 발명의 범위를 국한시키는 것으로 이해되어져서는 안될 것이다.The following examples are intended to illustrate the invention and should not be understood as limiting the scope of the invention.
<실시예 1. 유기게르마늄-효모 발효물의 제조>Example 1 Preparation of Organic Germanium-Yeast Fermentation
미강 추출물과 귀리 추출물을 제조하기 위하여, 미강과 귀리를 각각 세척, 건조하여 해당 시료 무게의 4배량의 증류수로 실온(20 내지 30℃)에서 4시간 동안 열수추출하였다. 이후, 각 추출물을 10,000rpm에서 20분간 원심분리하여 상등액을 취하고, 이를 여과하여 사용하였다. 비타민B 복합 수용액은 5중량% 비타민B1, 1중량% 비타민B2, 5중량% 비타민B3 및 잔량으로서 물을 혼합하였다. 최종적으로, 5중량%의 미강 추출물, 20중량%의 귀리 추출물, 5중량%의 비타민B 복합 수용액, 2중량%의 꿀, 0.1중량%의 효모 추출물, 5중량%의 레파게르마늄, 10중량%의 사카로마이세스 폼베(Saccharomyces pombe) 균 배양액과 배합하여, 37℃에서 4일 동안 발효하고, 10,000rpm에서 10분 동안 원심분리하여 얻은 상등액을 여과하여 유기게르마늄-효모 발효물을 제조하였다.To prepare rice bran extract and oat extract, rice bran and oats were washed and dried, respectively, and hot water extracted for 4 hours at room temperature (20 to 30 ° C.) with distilled water of 4 times the weight of the sample. Then, each extract was centrifuged at 10,000 rpm for 20 minutes to take a supernatant, which was used by filtration. The vitamin B complex aqueous solution was mixed with 5 wt% vitamin B 1, 1 wt% vitamin B 2, 5 wt% vitamin B 3 and water as a balance. Finally, 5% by weight of rice bran extract, 20% by weight oat extract, 5% by weight aqueous solution of vitamin B complex, 2% by weight honey, 0.1% by weight yeast extract, 5% by weight repagermanium, 10% by weight Saccharomyces pombe ) was combined with the culture medium, fermented for 4 days at 37 ℃, the supernatant obtained by centrifugation for 10 minutes at 10,000rpm was filtered to prepare an organic germanium- yeast fermentation.
<실험예 1. 유기게르마늄-효모 발효물의 세포독성>Experimental Example 1. Cytotoxicity of Organic Germanium-Yeast Fermentation>
Fibroblast 세포 및 macrophage 세포에 대한 유기게르마늄-효모 발효물의 세포독성을 알아보기 위하여 MTT(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) 시약을 사용하여 측정하였다. Fibroblast 세포 및 macrophage 세포(2X104cells)에 유기게르마늄-효모 발효물을 각 0, 50, 100, 250ppm이 되도록 가하여 37℃에서 24시간 배양하였다. MTT 용액을 최종 농도 1㎎/㎖이 되도록 첨가하여 4시간 배양한 후, 배지를 제거하고 색소를 디메틸설폭사이드(DMSO)로 용해시킨 후, 570㎚에서 흡광도를 측정하였다. 세포생존율은 하기 수학식 1에 대입하여 계산하였다.To determine the cytotoxicity of organo germanium-yeast fermentation on Fibroblast cells and macrophage cells, MTT (3- (4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide) reagent was used. Fibroblast cells and macrophage cells (2X10 4 cells) were added to the organic germanium- yeast fermentation to 0, 50, 100, 250ppm each and incubated at 37 ℃ for 24 hours. After adding the MTT solution to a final concentration of 1 mg / ml and incubating for 4 hours, the medium was removed, the pigment was dissolved in dimethyl sulfoxide (DMSO), and the absorbance was measured at 570 nm. Cell viability was calculated by substituting Equation 1 below.
[수학식 1][Equation 1]
세포 생존율(%) = (실험군의 흡광도/대조군의 흡광도) X 100% Cell viability = (absorbance of experimental group / absorbance of control group)
상기 실험 결과, 도 1에 나타난 바와 같이, 유기게르마늄-효모 발효물은 해당 농도에서 세포독성이 없는 것으로 나타났다.As a result of the experiment, as shown in Figure 1, the organic germanium- yeast fermentation was found to be cytotoxic at the corresponding concentration.
<실험예 2. 유기게르마늄-효모발효 여과물의 프로콜라겐 합성능>Experimental Example 2. Procollagen Synthesis of Organic Germanium-Yeast Fermented Filtrate>
본 발명의 유기게르마늄-효모 발효물의 프로콜라겐 합성능을 실험하고자, procollagen Type I C-Peptide (PIP) EIA Kit (TAKARA)를 사용하여 프로콜라겐의 합성능을 측정하였다. Human fibroblast CCD986-sk 세포주를 48웰 배양접시에 5X104cells/웰로 24시간 동안 전 배양한 후, 0, 50, 100, 250ppm의 유기게르마늄-효모 발효물과 유기게르마늄이 포함되지 않은 효모발효 여과물, 0.5% 레파게르마늄 수용액을 각각 24시간 처리하였고, 이때 양성 대조군으로 100ng/㎖ TGFβ를 사용하였다. 이후, 0.5% Triton X-100이 함유된 PBS를 사용하여 세포를 용해하고, 프로콜라겐의 양을 procollagen Type I C-Peptide (PIP) EIA Kit로 측량하여 도 2에 나타내었다.To test the procollagen synthesis ability of the organic germanium- yeast fermentation of the present invention, the procollagen type I C-Peptide (PIP) EIA Kit (TAKARA) was used to measure the synthesis ability of procollagen. Human fibroblast CCD986-sk cell line was pre-incubated for 24 hours at 5X10 4 cells / well in a 48 well dish, followed by 0, 50, 100, 250 ppm of organic germanium-yeast fermentation and yeast fermentation-free yeast fermentation filtrate. , 0.5% aqueous solution of lepagermanium was treated for 24 hours, at which time 100ng / ml TGFβ was used as a positive control. Then, cells were lysed using PBS containing 0.5% Triton X-100, and the amount of procollagen was measured by procollagen Type I C-Peptide (PIP) EIA Kit, and is shown in FIG. 2.
상기 실험 결과, 도 2에 나타난 바와 같이, 유기게르마늄-효모 발효물의 제조물과 효모발효 여과물은 250ppm에서 최대 약 1.5배의 프로콜라겐 생합성을 촉진하였고, 0.5% 레파게르마늄 수용액은 프로콜라겐 합성능에 영향을 주지 않았다.As a result of the experiment, as shown in Figure 2, the production of the organic germanium- yeast fermentation product and yeast fermentation filtrate promoted procollagen biosynthesis up to about 1.5 times at 250ppm, 0.5% aqueous solution of lepagermanium affects procollagen synthesis capacity Did not give.
<실험예 3. 레파게르마늄-효모발효 여과물의 멜라닌 합성 저해능>Experimental Example 3. Inhibition of Melanin Synthesis of Lepagermanium-Yeast Fermented Filtrate>
본 발명의 유기게르마늄-효모 발효물의 멜라닌 합성 저해능을 확인하고자 세포 내 멜라닌을 측량하였다. Melanoma B16F10 세포주를 2X105cell/웰이 들어가도록 6웰 플레이트에 분주하고 24시간 전 배양하였다. 배양 후, 배지를 제거하고, Phenol red free DMEM 배지에 α-MSH 100nM과 유기게르마늄-효모 발효물 및 효모발효 여과물, 0.5% 레파게르마늄 수용액을 농도별로 0, 50, 100, 250ppm을 처리하였다. 96시간 동안 배양한 후, 배지를 제거하고, PBS로 씻어준 다음 Trypsin-EDTA를 처리하고 2000rpm으로 2분동안 원심분리하여 세포를 얻었다. 이 세포에 10% DMSO가 들어간 1N NaOH를 200㎖ 넣고 교반한 후, 80℃에서 1시간 반응시키고, 96웰 플레이트에 100㎖씩 옮겨 405㎚에서 흡광도를 측정하였다. 위 용액을 단백질 정량하여 일정 단백질 당 멜라닌 값을 비교하여 도 3에 나타내었다.In order to determine the melanin synthesis inhibitory ability of the organic germanium- yeast fermentation of the present invention was measured melanin in the cell. Melanoma B16F10 cell line was aliquoted into 6-well plates containing 2 × 10 5 cells / well and incubated 24 hours ago. After incubation, the medium was removed, and 0, 50, 100, and 250 ppm of α-MSH 100nM, an organic germanium- yeast fermentation product, a yeast fermentation filtrate, and a 0.5% aqueous solution of lepagermanium were treated in Phenol red free DMEM medium. After incubation for 96 hours, the medium was removed, washed with PBS, treated with Trypsin-EDTA, and centrifuged at 2000 rpm for 2 minutes to obtain cells. 200 ml of 1N NaOH containing 10% DMSO was added to the cells, followed by stirring. The cells were reacted at 80 ° C for 1 hour, and then transferred to a 96-well plate in 100 ml portions, and the absorbance was measured at 405 nm. The above solution is shown in Figure 3 by comparing the melanin value per protein by protein quantification.
상기 실험 결과, 도 3에 나타난 바와 같이, 유기게르마늄-효모 발효물은 농도 의존적으로 100nM α-MSH에 의해 생성되는 멜라닌의 양을 감소 시켰으며, 0.5% 레파게르마늄 수용액은 250ppm에서 유의하게 α-MSH에 의해 생성되는 멜라닌의 양을 감소시켰다. 또한, 유기게르마늄-효모 발효물은 50ppm에서 α-MSH에 의해 생성되는 멜라닌의 양을 대조군 수준으로 감소시켰으며, 이는 효모발효 여과물(유기게르마늄으로 처리되지 않은)의 250ppm보다 우수하였다.As a result of the experiment, as shown in Figure 3, the organic germanium- yeast fermentation reduced the amount of melanin produced by 100nM α-MSH concentration-dependently, 0.5% aqueous solution of lepagermanium significantly at α-MSH at 250ppm Reduced the amount of melanin produced by In addition, organic germanium-yeast fermentation reduced the amount of melanin produced by α-MSH at 50 ppm to control levels, which was better than 250 ppm of yeast fermentation filtrate (not treated with organic germanium).
<실험예 4. 레파게르마늄-효모발효 여과물의 항염증능>Experimental Example 4. Anti-inflammatory Activity of Repagermanium-Yeast Fermented Filtrate>
본 발명의 유기게르마늄-효모 발효물의 항염증능 실험을 위해 TNF-α를 측량하였다. 마우스 대식세포 Raw264.7 세포주를 12 well cell culture plate에 1X106cells/웰로 분주하여 24 시간동안 전 배양 하였다. 24 시간 후 전 배양에 사용된 배지를 제거하고, 유기게르마늄-효모 발효물 및 효모발효 여과물, 0.5% 레파게르마늄 수용액을 0, 25, 50, 100ppm의 각 농도별로 첨가시킨 배지로 교체해 준 후 10분동안 배양하고, Normal 대조군을 제외한 나머지 시료 실험군에 LPS를 100ng/㎖ 농도로 처리하여서 20 시간 배양하여 염증을 유도하였다. 이후, 해당세포 배양액을 단백질 정량하여 실험에 사용하였다. TNF-α는 Mouse ELISA Ready Set GO kit (eBioscience)로 정량하여 도4에 나타내었다.TNF-α was measured for the anti-inflammatory test of the organic germanium-yeast fermentation of the present invention. Mouse macrophage Raw264.7 cell line was pre-incubated for 24 hours by dispensing 1 × 10 6 cells / well into 12 well cell culture plates. After 24 hours, the medium used for the preculture was removed, and the organic germanium- yeast fermentation product and the yeast fermentation filtrate, and 0.5% aqueous solution of lepagermanium were replaced with the medium added at each concentration of 0, 25, 50, and 100 ppm, followed by 10 Incubated for 1 minute, and incubated for 20 hours by treating LPS at a concentration of 100 ng / ml in the remaining test sample except the normal control group to induce inflammation. Subsequently, the cell cultures of the cells were quantified and used for experiments. TNF-α was quantified with a Mouse ELISA Ready Set GO kit (eBioscience) and is shown in FIG. 4.
상기 실험 결과, 도 4의 결과와 같이, 효모 발효 여과물은 100ng/㎖의 LPS에 의해 분비되는 TNF-α의 양을 50ppm부터 유의하게 감소시켰으며, 0.5% 레파게르마늄 수용액은 100ppm에서 유의하게 LPS에 의해 분비되는 TNF-α의 양을 감소 시켰다. 또한, 유기게르마늄-효모 발효물의 제조물은 25ppm에서도 LPS에 의해 분비되는 TNF-α의 양을 유의하게 감소시켰으며, 이는 50ppm의 효모 발효 여과물과 100ppm의 0.5% 레파게르마늄 수용액보다 향상된 값이다.As a result of the experiment, as shown in Figure 4, the yeast fermentation filtrate significantly reduced the amount of TNF-α secreted by 100ng / ㎖ LPS from 50ppm, 0.5% aqueous solution of lepagermanium significantly LPS at 100ppm Reduced the amount of TNF-α secreted by In addition, the preparation of organogermanium-yeast fermentation significantly reduced the amount of TNF-α secreted by LPS even at 25 ppm, which is an improvement over 50 ppm yeast fermentation filtrate and 100 ppm 0.5% repagermanium aqueous solution.
<실험예5. 레파게르마늄-효모발효 여과물의 티로시나아제 억제능>Experimental Example 5. Tyrosinase Inhibition of Lepagermanium-Yeast Fermentation Filtration>
본 발명의 유기게르마늄-효모 발효물의 티로시나아제 억제능을 확인하기 위해티로시나아제의 기질인 tyrosine을 반응시켜 그 억제율을 계산하였다. L-tyrosine을 0.3㎎/㎖의 농도로 인산칼륨완충용액(0.1M,pH6.)에 녹이고, 티로시나아제 역시 인산칼륨완충용액에 1250 U/㎖이 되도록 용해하였다. 유기게르마늄-효모 발효물 및 효모발효 여과물, 0.5% 레파게르마늄 수용액을 각각 50, 100, 500, 2500ppm으로 증류수(대조군)에 농도별로 희석하여 시료로 사용하였고, 150㎕의 시료에 50㎕의 티로시나아제 용액을 첨가하여 37℃에 10분간 방치하였다. 이후, 100㎕의 L-tyrosine 용액을 첨가하여 37℃에 10분 동안 반응시키고, 0℃에서 5분동안 효소반응을 정지시킨 후 475㎚에서 흡광도를 측정하였다. 티로시나아제의 억제율은 하기 수학식 2에 대입하여 계산하였다(표 1).In order to confirm the tyrosinase inhibitory ability of the organic germanium-yeast fermentation of the present invention, the inhibition rate of tyrosine, which is a substrate of tyrosinase, was reacted. L-tyrosine was dissolved in potassium phosphate buffer solution (0.1 M, pH 6.) at a concentration of 0.3 mg / ml, and tyrosinase was also dissolved in potassium phosphate buffer solution to 1250 U / ml. The organic germanium- yeast fermentation product, yeast fermentation filtrate, and 0.5% aqueous solution of lepagermanium were diluted in distilled water (control) at 50, 100, 500, and 2500 ppm, respectively, and used as samples. Cinase solution was added and left at 37 ° C for 10 minutes. Thereafter, 100 μl of L-tyrosine solution was added to react at 37 ° C. for 10 minutes, the enzyme reaction was stopped at 0 ° C. for 5 minutes, and the absorbance was measured at 475 nm. The inhibition rate of tyrosinase was calculated by substituting Equation 2 below (Table 1).
[수학식 2][Equation 2]
티로시나아제 억제율(%) = (대조군의 흡광도 - 실험군의 흡광도)/대조군의 흡광도 X 100% Tyrosinase inhibition = (absorbance of control-absorbance of experimental group) / absorbance of
상기 실험 결과, 유기게르마늄-효모 발효물의 IC50값은 467.4ppm으로, 효모발효 여과물의 IC50값 566.2ppm 대비 상향된 효능을 갖는 것으로 확인하였다.As a result of the experiment, the IC 50 value of the organic germanium- yeast fermentation was 467.4ppm, it was confirmed that the yeast fermentation filtrate has an increased efficacy compared to 566.2ppm IC 50 value.
이상에서 본 발명은 기재된 구체예에 대해서만 상세히 설명되었지만 본 발명의 기술사상 범위 내에서 다양한 변형 및 수정이 가능함은 당업자에게 있어서 명백한 것이며, 이러한 변형 및 수정이 첨부된 특허청구범위에 속함은 당연한 것이다. Although the present invention has been described in detail only with respect to the described embodiments, it will be apparent to those skilled in the art that various modifications and variations are possible within the technical scope of the present invention, and such modifications and modifications are within the scope of the appended claims.
(도면 부호 없음)(Not drawing)
Claims (8)
(2) 상기 원물 혼합물에 유기게르마늄을 첨가하는 유기게르마늄 첨가단계; 및
(3) 유기게르마늄이 첨가된 원물 혼합물에 효모균을 접종하고, 배양시키는 배양단계;
를 포함함을 특징으로 하는 피부 미백, 피부 항주름 및 항염증 효능을 갖는 유기게르마늄 보조 효모 발효물의 제조방법.(1) a mixing step of preparing a raw material mixture including rice bran extract, oat extract, sugar, aqueous vitamin B complex and yeast extract;
(2) an organic germanium addition step of adding organic germanium to the raw material mixture; And
(3) a culture step of inoculating and incubating the yeast bacteria in the raw material mixture to which the organic germanium is added;
Method for producing an organic germanium supplementary yeast fermentation product having skin whitening, skin anti-wrinkle and anti-inflammatory effect, comprising a.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180049721A KR102070168B1 (en) | 2018-04-30 | 2018-04-30 | Organic germanium assisted yeast fermentated material having skin whitening, skin antiwrinkle and antiinflammation effect |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180049721A KR102070168B1 (en) | 2018-04-30 | 2018-04-30 | Organic germanium assisted yeast fermentated material having skin whitening, skin antiwrinkle and antiinflammation effect |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20190125653A true KR20190125653A (en) | 2019-11-07 |
KR102070168B1 KR102070168B1 (en) | 2020-01-28 |
Family
ID=68578990
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020180049721A KR102070168B1 (en) | 2018-04-30 | 2018-04-30 | Organic germanium assisted yeast fermentated material having skin whitening, skin antiwrinkle and antiinflammation effect |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102070168B1 (en) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110772468A (en) * | 2019-12-12 | 2020-02-11 | 山东福瑞达生物科技有限公司 | Oat and tremella fermentation product filtrate and preparation method thereof |
CN113559045A (en) * | 2021-08-26 | 2021-10-29 | 浙江辰海生命科学有限公司 | Oat bran fermentation product, skin external preparation containing oat bran fermentation product, and preparation method and application of oat bran fermentation product |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07194370A (en) * | 1993-11-29 | 1995-08-01 | Daijy Corp | Yeast containing organic germanium and its preparation |
KR100658296B1 (en) * | 2000-01-17 | 2006-12-14 | 주식회사 엘지생활건강 | A cosmetic composition containing organic germanium for wrinkle reduction |
KR20070067549A (en) * | 2005-12-23 | 2007-06-28 | 주식회사 두산 | Composition for protecting and improving skin comprising the rice bran fermented by lactic acid bacteria |
KR20120107557A (en) * | 2011-03-22 | 2012-10-04 | 이강옥 | Rice bran fermentation extracts with chlorophyll and the manufacturing method thereof |
-
2018
- 2018-04-30 KR KR1020180049721A patent/KR102070168B1/en active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH07194370A (en) * | 1993-11-29 | 1995-08-01 | Daijy Corp | Yeast containing organic germanium and its preparation |
KR100658296B1 (en) * | 2000-01-17 | 2006-12-14 | 주식회사 엘지생활건강 | A cosmetic composition containing organic germanium for wrinkle reduction |
KR20070067549A (en) * | 2005-12-23 | 2007-06-28 | 주식회사 두산 | Composition for protecting and improving skin comprising the rice bran fermented by lactic acid bacteria |
KR20120107557A (en) * | 2011-03-22 | 2012-10-04 | 이강옥 | Rice bran fermentation extracts with chlorophyll and the manufacturing method thereof |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110772468A (en) * | 2019-12-12 | 2020-02-11 | 山东福瑞达生物科技有限公司 | Oat and tremella fermentation product filtrate and preparation method thereof |
CN113559045A (en) * | 2021-08-26 | 2021-10-29 | 浙江辰海生命科学有限公司 | Oat bran fermentation product, skin external preparation containing oat bran fermentation product, and preparation method and application of oat bran fermentation product |
Also Published As
Publication number | Publication date |
---|---|
KR102070168B1 (en) | 2020-01-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Taofiq et al. | Mushrooms extracts and compounds in cosmetics, cosmeceuticals and nutricosmetics—A review | |
US8545905B2 (en) | Whitening cosmetic composition containing green tea extract | |
KR100825450B1 (en) | Skin anti-wrinkle cosmetics composition containing Forsythiae Fruit extract | |
US10350156B2 (en) | Method for preparing cosmetic composition containing fermented ginseng berry Pleurotus ferulae product and use thereof | |
KR101452770B1 (en) | Cosmetic composition comprising lactobacillus fermented solution having anti-oxidation, whitening and anti-wrinkle effect | |
KR20190014477A (en) | Tremella fuciformis extraxt, preparation method thereof and Use the same | |
KR101229748B1 (en) | Cosmetic compositions containing fermented extract of Hippophae rhamnoides L | |
WO2009145345A1 (en) | Preparation for external use containing fungus of the genus cordyceps, cordyceps sobolifera (hill.) berk. et br. | |
KR20170132388A (en) | Composition comprising for skin-whitening and anti-wrinkling extract of Rumex acetosella L. or extract of Hydrangea serrata | |
KR102070168B1 (en) | Organic germanium assisted yeast fermentated material having skin whitening, skin antiwrinkle and antiinflammation effect | |
KR20140114239A (en) | The skin whitening cosmetic composition | |
KR101837020B1 (en) | Separation method for saponins from Sapindus mukorossi and cosmetic composition containing the same | |
KR20100006796A (en) | Anti-aging cosmetic composition comprising herb ferment extract | |
KR20200098153A (en) | Composition for preventing or improving of skin wrinkle or skin photo-aging comprising fermented extract of Dendropanax morbifera and purple sweet potato as an active ingredient | |
KR20120085369A (en) | skin-whitening, anti-bacterial and anti-inflammatory composition comprising a fermented juice of jujube and grape | |
KR102462347B1 (en) | Cosmetic composition for improving skin barrier function and anti-wrinkle effects comprising fermented eggplant extract as an active ingredient | |
KR101803757B1 (en) | Cosmetic composition containing natural complex fermented extracts | |
KR20090079277A (en) | Cosmetic composition with the anti-oxidant, anti-inflammatory and anti-wrinkled effect | |
KR102405511B1 (en) | Composition for skin regeneration, improvement or treatment damaged by ultraviolet light containing blackberry fermented product as an active ingredient | |
KR101984781B1 (en) | Cosmetic composition for improving whitening, wrinkle and elasticity of skin comprising persimmon byproduct extract produced by enzymatic hydrolysis and ultra high pressure homogenization as effective component | |
KR101997231B1 (en) | Cosmetic composition containing enzyme-treated honey extract | |
KR20140081137A (en) | A skin-care agent containig Morchella esculenta fruit body extract or Morchella esculenta mycelium extract | |
TW202102239A (en) | Antiaging agent, antioxidant, antiinflammatory agent and whitening agent, and cosmetic | |
KR102014961B1 (en) | Composition for anti oxidation containing extract of soybean pod | |
KR101207560B1 (en) | Cosmetic composition comprising the extract of Cleyera japonica as active ingredient |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |